Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

N-Alkyl Isofagomine Lactams: Synthesis, Glycosidase Inhibition, and Antimicrobial Assessments

  • Moreń, Monika
  • Pereira Lourenço, Ana Laura
  • Cerdà-Cuéllar, Marta
  • Kochanowski, Karl
  • Jørgensen, Kåre B.
  • Sydnes, Magne O.
  • López, Óscar
  • Lindbäck, Emil
A series of six N-alkyl isofagomine lactam derivatives were synthesized over ten steps from D-arabinose. The compounds were evaluated as glycosidase inhibitors. It was found that the N-alkyl groups have a detrimental effect on the glycosidase inhibition activities, as the N-alkyl isofagomine lactam derivatives are much less potent glycosidase inhibitors than native isofagomine lactam., AP is supported by a European Union Horizon Europe MSCA DNID grant (grant number 101073263). KK is supported by the Spanish Ministry of Research and Innovation (Grant number: RYC2021-033035-I). MM, KBJ, MOS, and EL are supported by the University of Stavanger. Ó.L. thanks Grant PID2020-116460RBI00 funded by MCIN/AEI/10.13039/501100011033 for financial support., info:eu-repo/semantics/acceptedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

SET-M33 peptide as a selective in vitro antimicrobial agent against the porcine respiratory pathogen Glaesserella parasuis

  • Pereira Lourenço, Ana L.
  • el Khatab, Oussama Rouam
  • Falciani, Chiara
  • Pini, Alessandro
  • Aragon, Virginia
  • Cerdà-Cuéllar, Marta
  • Kochanowski, Karl
As we face the threat from bacterial pathogens that are resistant to many conventional antibiotics, many current research efforts focus on expanding our arsenal of antimicrobial compounds. However, identifying use cases in which such new antimicrobials can effectively target pathogens while minimizing collateral damage in the commensal microbiota remains a challenge. To tackle this challenge, we focused on one new antimicrobial, the synthetic antimicrobial peptide SET-M33, and examined its ability to target porcine respiratory pathogens and a collection of porcine commensal nasal microbiota members in vitro. Our experiments revealed three key results. First, there were large differences in SET-M33 sensitivity across the tested strains. In particular, pathogenic Glaesserella parasuis was highly sensitive to SET-M33 at concentrations that did not affect the growth of most commensal strains. Second, some of the tested commensal strains (Rothia nasimurium and Staphylococcus aureus) were able to inactivate SET-M33 during in vitro cultivation. Third, despite this potential for SET-M33 inactivation by commensal strains, SET-M33 was still able to selectively eliminate pathogenic G. parasuis from in vitro co-cultures that also contained R. nasimurium. Overall, this study highlights the substantial complexity that emerges from the interplay between antimicrobials, pathogens, and commensals, even within a comparatively simple in vitro system, and provides a template for identifying suitable use cases for newly developed antimicrobials., We thank Marcelo Gottschalk for kindly providing the bacterial strains Streptococcus suis P1/7 and Actinobacillus pleuropneumoniae 4074. This project received support from a European Union Horizon Europe MSCA DN-ID grant (101073263, “Stop Spread Bad Bugs” consortium). A.P. acknowledges funding from the Italian Ministry of Education, University and Research (PRIN 2022, CUP B53D23003680006). O.R.E.K. is supported by an intramural IRTA PhD fellowship. K.K. is supported by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033 and PID2023 152210NA-I00 /AEI/10.13039/501100011033). The CERCA Program from the Generalitat de Catalunya is also acknowledged., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Gelatin-Based Coating for the Controlled and Localized Delivery of Tetrabranched Antimicrobial Peptide in Cardiac Implantable Devices

  • Maranesi, Alessia
  • Ferrari, Aldo
  • Falciani, Chiara
  • Pini, Alessandro
  • Kochanowski, Karl
  • Cerdà-Cuéllar, Marta
Infections associated with cardiac implantable electronic devices (CIEDs) significantly increase patient morbidity and mortality and impose a substantial burden on healthcare systems. Current preventive strategies based on antibiotics are increasingly challenged by the emergence of antimicrobial resistance, while complex surface modification approaches often suffer from limited practicality and translational barriers. In this study, we propose the integration of a structurally complex, tetra-branched antimicrobial peptide (SET-M33) within a gelatin methacryloyl (GelMA) hydrogel to create an antimicrobial-releasing coating for CIED surfaces. By tuning the properties of the GelMA matrix, we achieved controlled peptide release tailored to clinically relevant timeframes. The resulting M33-GelMA coating demonstrated strong in vitro efficacy in preventing bacterial growth and adhesion by six clinically relevant pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumannii, Escherichia coli, Enterococcus faecium, Stenotrophomonas maltophilia), achieving up to a 9-log reduction in bacterial load. Overall, this work provides a practical and translatable strategy for leveraging more stable, next-generation antimicrobial peptides to reduce postoperative CIED infections and associated healthcare burdens., We thank Oscar Quijada Pich for kindly providing the bacterial strain S. aureus ATCC BAA-2856. This project received support from the European Union Horizon Europe MSCA DN-ID grant (101073263, “Stop Spread Bad Bugs” consortium). AP acknowledges funding from the Italian Ministry of Education, University and Research (PRIN 2022, CUP B53D23003680006). KK is supported by the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). The CERCA Program from the Generalitat de Catalunya is also acknowledged., info:eu-repo/semantics/publishedVersion
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

SET-M33 loaded biosynthesized cellulose as effective protection against S. aureus biofilm formation

  • Mohammadi, Sajad
  • Maranesi, Alessia|||0009-0000-9696-4119
  • de Bruijn, Adrianus C.J.M.
  • Castañon, Ismael
  • Gierlich, Piotr
  • Falciani, Chiara
  • Pini, Alessandro
  • Beusekom, Heleen M. M. van|||0000-0002-2930-1152
  • Ferrari, Aldo
  • Unger, Wendy
Staphylococcus aureus is the most common pathogen responsible for postoperative infections associated with cardiac implantable electronic devices (CIEDs), primarily due to its biofilm-forming capability on implant substrates. Protective envelopes, which sustain the local elution of antibiotics, significantly reduce the risk of CIED infection and biofilm formation. However, they are not equipped to counteract emerging bacterial resistance to antibiotics. Antimicrobial peptides (AMPs) can effectively erase contaminating bacteria, without eliciting resistance. Here, we explored the antimicrobial efficacy of biosynthesized cellulose (BC), a natural biopolymer used in protective envelopes, in combination with two synthetic AMPs: SET-M33D and Mastoparan X (MPX). The BC/AMPs combination inhibited bacterial attachment and subsequent biofilm formation significantly better than native BC or AMP coated titanium substrates, as revealed by full factorial design (FFD) experiments. The outcomes of FFD were used to develop a regression model that estimates the interaction between influential parameters and their impacts on response value. Furthermore, SEM imaging confirmed the superior antibiofilm activity of BC/SET-M33D compared to BC/MPX. We demonstrated that the protective function against S. aureus ATCC29213 may be linked to the downregulation of the biofilm associated gene icaA. The results reported demonstrate the feasibility of exploiting BC as AMP carrier for inhibiting biofilm formation in conditions relevant to deployment of CIEDs. While further in vivo evaluation is needed, this approach may offer a promising path to address antimicrobial resistance in the management of post-operative infections associated with CIED implant., This work was supported by European Union Horizon Europe MSCA programme (grant agreement number 101073263 [SSBB])., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SET-M33 peptide as a selective in vitro antimicrobial agent against the porcine respiratory pathogen Glaesserella parasuis

  • Pereira Lourenço, Ana L.
  • el Khatab, Oussama Rouam
  • Falciani, Chiara
  • Pini, Alessandro
  • Aragon, Virginia
  • Cerdà-Cuéllar, Marta
  • Kochanowski, Karl
As we face the threat from bacterial pathogens that are resistant to many conventional antibiotics, many current research efforts focus on expanding our arsenal of antimicrobial compounds. However, identifying use cases in which such new antimicrobials can effectively target pathogens while minimizing collateral damage in the commensal microbiota remains a challenge. To tackle this challenge, we focused on one new antimicrobial, the synthetic antimicrobial peptide SET-M33, and examined its ability to target porcine respiratory pathogens and a collection of porcine commensal nasal microbiota members in vitro. Our experiments revealed three key results. First, there were large differences in SET-M33 sensitivity across the tested strains. In particular, pathogenic Glaesserella parasuis was highly sensitive to SET-M33 at concentrations that did not affect the growth of most commensal strains. Second, some of the tested commensal strains (Rothia nasimurium and Staphylococcus aureus) were able to inactivate SET-M33 during in vitro cultivation. Third, despite this potential for SET-M33 inactivation by commensal strains, SET-M33 was still able to selectively eliminate pathogenic G. parasuis from in vitro co-cultures that also contained R. nasimurium. Overall, this study highlights the substantial complexity that emerges from the interplay between antimicrobials, pathogens, and commensals, even within a comparatively simple in vitro system, and provides a template for identifying suitable use cases for newly developed antimicrobials., We thank Marcelo Gottschalk for kindly providing the bacterial strains Streptococcus suis P1/7 and Actinobacillus pleuropneumoniae 4074. This project received support from a European Union Horizon Europe MSCA DN-ID grant (101073263, “Stop Spread Bad Bugs” consortium). A.P. acknowledges funding from the Italian Ministry of Education, University and Research (PRIN 2022, CUP B53D23003680006). O.R.E.K. is supported by an intramural IRTA PhD fellowship. K.K. is supported by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033 and PID2023 152210NA-I00 /AEI/10.13039/501100011033). The CERCA Program from the Generalitat de Catalunya is also acknowledged., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gelatin-Based Coating for the Controlled and Localized Delivery of Tetrabranched Antimicrobial Peptide in Cardiac Implantable Devices

  • Maranesi, Alessia
  • Ferrari, Aldo
  • Falciani, Chiara
  • Pini, Alessandro
  • Kochanowski, Karl
  • Cerdà-Cuéllar, Marta
Infections associated with cardiac implantable electronic devices (CIEDs) significantly increase patient morbidity and mortality and impose a substantial burden on healthcare systems. Current preventive strategies based on antibiotics are increasingly challenged by the emergence of antimicrobial resistance, while complex surface modification approaches often suffer from limited practicality and translational barriers. In this study, we propose the integration of a structurally complex, tetra-branched antimicrobial peptide (SET-M33) within a gelatin methacryloyl (GelMA) hydrogel to create an antimicrobial-releasing coating for CIED surfaces. By tuning the properties of the GelMA matrix, we achieved controlled peptide release tailored to clinically relevant timeframes. The resulting M33-GelMA coating demonstrated strong in vitro efficacy in preventing bacterial growth and adhesion by six clinically relevant pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumannii, Escherichia coli, Enterococcus faecium, Stenotrophomonas maltophilia), achieving up to a 9-log reduction in bacterial load. Overall, this work provides a practical and translatable strategy for leveraging more stable, next-generation antimicrobial peptides to reduce postoperative CIED infections and associated healthcare burdens., We thank Oscar Quijada Pich for kindly providing the bacterial strain S. aureus ATCC BAA-2856. This project received support from the European Union Horizon Europe MSCA DN-ID grant (101073263, “Stop Spread Bad Bugs” consortium). AP acknowledges funding from the Italian Ministry of Education, University and Research (PRIN 2022, CUP B53D23003680006). KK is supported by the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). The CERCA Program from the Generalitat de Catalunya is also acknowledged., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

N-Alkyl Isofagomine Lactams: Synthesis, Glycosidase Inhibition, and Antimicrobial Assessments

  • Moreń, Monika
  • Pereira Lourenço, Ana Laura
  • Cerdà-Cuéllar, Marta
  • Kochanowski, Karl
  • Jørgensen, Kåre B.
  • Sydnes, Magne O.
  • López, Óscar
  • Lindbäck, Emil
A series of six N-alkyl isofagomine lactam derivatives were synthesized over ten steps from D-arabinose. The compounds were evaluated as glycosidase inhibitors. It was found that the N-alkyl groups have a detrimental effect on the glycosidase inhibition activities, as the N-alkyl isofagomine lactam derivatives are much less potent glycosidase inhibitors than native isofagomine lactam., AP is supported by a European Union Horizon Europe MSCA DNID grant (grant number 101073263). KK is supported by the Spanish Ministry of Research and Innovation (Grant number: RYC2021-033035-I). MM, KBJ, MOS, and EL are supported by the University of Stavanger. Ó.L. thanks Grant PID2020-116460RBI00 funded by MCIN/AEI/10.13039/501100011033 for financial support., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SET-M33 loaded biosynthesized cellulose as effective protection against S. aureus biofilm formation

  • Mohammadi, Sajad
  • Maranesi, Alessia
  • de Bruijn, Adrianus C.J.M.
  • Castañon, Ismael
  • Gierlich, Piotr
  • Falciani, Chiara
  • Pini, Alessandro
  • Beusekom, Heleen M. M. van
  • Ferrari, Aldo
  • Unger, Wendy
Staphylococcus aureus is the most common pathogen responsible for postoperative infections associated with cardiac implantable electronic devices (CIEDs), primarily due to its biofilm-forming capability on implant substrates. Protective envelopes, which sustain the local elution of antibiotics, significantly reduce the risk of CIED infection and biofilm formation. However, they are not equipped to counteract emerging bacterial resistance to antibiotics. Antimicrobial peptides (AMPs) can effectively erase contaminating bacteria, without eliciting resistance. Here, we explored the antimicrobial efficacy of biosynthesized cellulose (BC), a natural biopolymer used in protective envelopes, in combination with two synthetic AMPs: SET-M33D and Mastoparan X (MPX). The BC/AMPs combination inhibited bacterial attachment and subsequent biofilm formation significantly better than native BC or AMP coated titanium substrates, as revealed by full factorial design (FFD) experiments. The outcomes of FFD were used to develop a regression model that estimates the interaction between influential parameters and their impacts on response value. Furthermore, SEM imaging confirmed the superior antibiofilm activity of BC/SET-M33D compared to BC/MPX. We demonstrated that the protective function against S. aureus ATCC29213 may be linked to the downregulation of the biofilm associated gene icaA. The results reported demonstrate the feasibility of exploiting BC as AMP carrier for inhibiting biofilm formation in conditions relevant to deployment of CIEDs. While further in vivo evaluation is needed, this approach may offer a promising path to address antimicrobial resistance in the management of post-operative infections associated with CIED implant., This work was supported by European Union Horizon Europe MSCA programme (grant agreement number 101073263 [SSBB])., Peer Reviewed, Postprint (published version)